Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies.
Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA
JAMA Dermatol. 2020 Apr 8; doi: 10.1001/jamadermatol.2020.0208.

PMID:
    32267477
    [PubMed - as supplied by publisher]
Related citations


Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial.
Schöder H, Polley MY, Knopp MV, Hall NC, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz A, Cheson BD, Wagner-Johnston ND, Kahl B, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL
Blood. 2020 Mar 13; pii: blood.2019003277. doi: 10.1182/blood.2019003277.

PMID:
    32232481
    [PubMed - as supplied by publisher]
Related citations


The justification of vincristine dose capping: tradition, tradition…tradition!
Bartlett NL
Leuk Lymphoma. 2020 Mar 26; 1-3. doi: 10.1080/10428194.2020.1742907.

PMID:
    32212887
    [PubMed - as supplied by publisher]
Related citations


Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos D, Bartlett NL, Braunschweig I, Jiang Y, Kim JJ, Zheng L, Rossi JM, Locke FL
Blood. 2020 Mar 16; pii: blood.2019004162. doi: 10.1182/blood.2019004162.

PMID:
    32181801
    [PubMed - as supplied by publisher]
Related citations


Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403.
Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, Leonard JP, Cheson BD
Am J Hematol. 2020 Mar 13; doi: 10.1002/ajh.25783.

PMID:
    32170769
    [PubMed - as supplied by publisher]
Related citations


First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20<sup>+</sup> Non-Hodgkin Lymphomas.
Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, Mu XJ, Deng S, Ching KA, Chen Y, Davis CB, Huang B, Fly KD, Thall A, Woolfson A, Bartlett NL
Clin Cancer Res. 2020 Mar 6; pii: clincanres.2973.2019. doi: 10.1158/1078-0432.CCR-19-2973.

PMID:
    32144134
    [PubMed - as supplied by publisher]
Related citations


Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.
Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce R, Armand P, Jacobsen E
Blood Adv. 2020 Mar 10; 4(5)858-867. doi: 10.1182/bloodadvances.2019001355.

PMID:
    32126141
    [PubMed - in process]
Related citations


Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A
Blood. 2020 Mar 5; 135(10)735-742. doi: 10.1182/blood.2019003127.

PMID:
    31945149
    [PubMed - in process]
Related citations


Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle.
Bartlett NL
J Clin Oncol. 2020 Mar 1; 38(7)662-668. doi: 10.1200/JCO.19.02816.

PMID:
    31922929
    [PubMed - in process]
Related citations


Implication of Rituximab Infusion Reactions on Clinical Outcomes in Patients With Diffuse Large B-cell Lymphoma: A Single Institution Experience.
Patel DA, Johanns TM, Trinkaus K, Bartlett NL, Wagner-Johnston N, Cashen AF
Clin Lymphoma Myeloma Leuk. 2019 Dec; 19(12)806-811. doi: 10.1016/j.clml.2019.09.604.

PMID:
    31648954
    [PubMed - in process]
Related citations


Reply to T.M. Weis et al.
Bartlett NL, Wilson WH, Leonard JP
J Clin Oncol. 2019 Nov 1; 37(31)2953. doi: 10.1200/JCO.19.01617.

PMID:
    31532721
    [PubMed - in process]
Related citations


Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW
Blood. 2019 Oct 10; 134(15)1238-1246. doi: 10.1182/blood.2019000719.

PMID:
    31331918
    [PubMed - indexed for MEDLINE]
Related citations


Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome.
Fakhri B, Cashen AF, Duncavage EJ, Watkins MP, Wartman LD, Bartlett NL
Clin Lymphoma Myeloma Leuk. 2019 Sep; 19(9)e532-e535. doi: 10.1016/j.clml.2019.05.015.

PMID:
    31279773
    [PubMed - in process]
Related citations


NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H
J Natl Compr Canc Netw. 2019 Jun 1; 17(6)650-661. doi: 10.6004/jnccn.2019.0029.

PMID:
    31200358
    [PubMed - in process]
Related citations


Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL
Cancer. 2019 Oct 1; 125(19)3378-3389. doi: 10.1002/cncr.32289.

PMID:
    31174236
    [PubMed - in process]
Related citations


Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP
Lancet Oncol. 2019 Jul; 20(7)998-1010. doi: 10.1016/S1470-2045(19)30091-9.

PMID:
    31101489
    [PubMed - in process]
Related citations


Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma.
Valenzuela CV, Bartlett NL, Bradley JP
Ear Nose Throat J. 2019 Jun; 98(5)E30-E31. doi: 10.1177/0145561319840534.

PMID:
    30961378
    [PubMed - indexed for MEDLINE]
Related citations


Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP
J Clin Oncol. 2019 Jul 20; 37(21)1790-1799. doi: 10.1200/JCO.18.01994.

PMID:
    30939090
    [PubMed - in process]
Related citations


Progressive multifocal leukoencephalopathy treated with nivolumab.
Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB
J Neurovirol. 2019 Apr; 25(2)284-287. doi: 10.1007/s13365-019-00738-x.

PMID:
    30864100
    [PubMed - in process]
Related citations


Parameters for Validating a Hospital Pneumatic Tube System.
Farnsworth CW, Webber DM, Krekeler JA, Budelier MM, Bartlett NL, Gronowski AM
Clin Chem. 2019 May; 65(5)694-702. doi: 10.1373/clinchem.2018.301408.

PMID:
    30808643
    [PubMed - indexed for MEDLINE]
Related citations